MaxCyteMXCT
Market Cap: $398M
About: MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Employees: 143
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
2.23% less ownership
Funds ownership: 67.6% [Q1] → 65.37% (-2.23%) [Q2]
7% less funds holding
Funds holding: 123 [Q1] → 114 (-9) [Q2]
9% less capital invested
Capital invested by funds: $296M [Q1] → $269M (-$27M) [Q2]
43% less call options, than puts
Call options by funds: $8K | Put options by funds: $14K
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
Research analyst outlook
We haven’t received any recent analyst ratings for MXCT.